Nutrition & Metabolism (Dec 2007)

Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?

  • Hopkins Paul N,
  • Tang Weihong,
  • Wagenknecht Lynne,
  • Arnett Donna,
  • Province Michael A,
  • Kraja Aldi T,
  • Djoussé Luc,
  • Borecki Ingrid B

DOI
https://doi.org/10.1186/1743-7075-4-28
Journal volume & issue
Vol. 4, no. 1
p. 28

Abstract

Read online

Abstract Context The metabolic syndrome (MetS), in addition to its lipid, metabolic, and anthropomorphic characteristics, is associated with a prothrombotic and the proinflammatory state. However, the relationship of inflammatory biomarkers to MetS is not clear. Objective To study the association between a group of thrombotic and inflammatory biomarkers and the MetS. Methods Ten conventional MetS risk variables and ten biomarkers were analyzed. Correlations, factor analysis, hexagonal binning, and regression of each biomarker with the National Cholesterol Education Program (NCEP) MetS categories were performed in the Family Heart Study (n = 2,762). Results Subjects in the top 75% quartile for plasminogen activator inhibitor-1 (PAI1) had a 6.9 CI95 [4.2–11.2] greater odds (p Conclusion PAI1 is an important risk factor for MetS. It correlates significantly with most of the variables studied, clusters in two latent factors related to obesity and lipids, and demonstrates the greatest relative odds of the 10 biomarkers studied with respect to the MetS. Three other biomarkers, CRP, IL6, and fibrinogen associate also importantly with the MetS cluster. These 4 biomarkers can contribute in the MetS risk assessment.